Bigbear Pharmaceutical·Medication Guide

• Rezurock (Belumosudil) Price: Annual Treatment Cost vs. Insurance Coverage

  The price of Besudil (besuprost sodium) varies depending on factors such as dosage, region, and purchase channel, typically ranging from 300-800 yuan ···【Read More】

  Update: 2026-04-01Source: Haiou HealthViews: 106

• Belumosudil Cost 2026: How Much Does Rezurock Cost Per Month?

  Bexotegrast is an investigational drug for the treatment of idiopathic pulmonary fibrosis (IPF). It has not yet been officially approved for marketing···【Read More】

  Update: 2026-04-01Source: Haiou HealthViews: 138

• Rezurock (belumosudil) Product Information - Price - Efficacy & Uses - Side Effects

  On July 17, 2021, Kadmon Holdings announced that the U.S. Food and Drug Administration (FDA) has approved Rezurock (belumosudil) 200 mg once daily (QD···【Read More】

  Update: 2026-04-01Source: Haiou HealthViews: 114

• New Drug for Chronic Graft-versus-Host Disease (cGVHD)! FDA Approves First ROCK2 Inhibitor Rezurock

  Kadmon Holdings recently announced that the U.S. Food and Drug Administration (FDA) has approved Rezurock (belumosudil) 200 mg once daily (QD) for the···【Read More】

  Update: 2026-04-01Source: Haiou HealthViews: 119

• REZUROCK has been included in the NCCN Guidelines

  Chronic graft-versus-host disease (cGVHD) is a complication that can occur after allogeneic stem cell transplantation. The transplanted immune cells (···【Read More】

  Update: 2026-04-01Source: Haiou HealthViews: 105

• Potential Drug Interactions with Deucravacitinib

  Inform your healthcare provider about all medications you are taking, including prescription drugs, over-the-counter products, vitamins, and herbal su···【Read More】

  Update: 2026-04-01Source: Haiou HealthViews: 110

• How to Store Deucravacitinib

  Store at room temperature between 68°F and 77°F (20°C and 25°C).Keep all medications away from children and pets.【Read More】

  Update: 2026-04-01Source: Haiou HealthViews: 125

• How to Take Deucravacitinib

  Take deucravacitinib tablets precisely as instructed by your healthcare provider.This medication should be taken once daily.Tablets may be taken with ···【Read More】

  Update: 2026-04-01Source: Haiou HealthViews: 120

• Deucravacitinib Price in the US vs. Overseas: How to Access Affordable Generic Options

  The price of deuterocelexitinib is affected by region, dosage, and health insurance policies. Specific costs should be confirmed with your local hospi···【Read More】

  Update: 2026-03-31Source: Haiou HealthViews: 126

• How Much Does Deucravacitinib Cost with Insurance? Out-of-Pocket Costs & Copay Assistance in 202

  Deuterocactinib is an oral targeted therapy primarily used to treat moderate to severe plaque psoriasis and other immune-related diseases. Its price f···【Read More】

  Update: 2026-03-31Source: Haiou HealthViews: 136

• Promacta vs. Generic Deucravacitinib 2026: Cost Comparison, Savings, and What You Need to Know

  The current domestic price of deuterocelexitinib (14 tablets) is approximately 4300-4800 RMB per box (14 tablets). The specific price may fluctuate sl···【Read More】

  Update: 2026-03-31Source: Haiou HealthViews: 113

• Deucravacitinib Achieves Success in Phase 3 Clinical Trial for Plaque Psoriasis!

  Bristol-Myers Squibb (BMS) recently announced that the pivotal Phase 3 POETYK PSO-1 study evaluating the novel anti-inflammatory drug deucravacitinib ···【Read More】

  Update: 2026-03-31Source: Haiou HealthViews: 137

• New Drug for Moderate to Severe Plaque Psoriasis in Adults! US FDA Approves Sotyktu (deucravacitinib

  On September 9, 2022, Bristol-Myers Squibb announced that the US Food and Drug Administration (FDA) has approved Sotyktu (deucravacitinib) for the tre···【Read More】

  Update: 2026-03-31Source: Haiou HealthViews: 125

• New Drug for Moderate to Severe Plaque Psoriasis in Adults! US FDA Approves Sotyktu (deucravacitinib

  On September 9, 2022, Bristol-Myers Squibb announced that the US Food and Drug Administration (FDA) has approved Sotyktu (deucravacitinib) for the tre···【Read More】

  Update: 2026-03-31Source: Haiou HealthViews: 124

• Sotyktu (deucravacitinib) Demonstrates Good Safety and Tolerability in Treating Moderate to Severe P

  Bristol-Myers Squibb announced on September 9, 2022, that the U.S. Food and Drug Administration (FDA) has approved Sotyktu (deucravacitinib) for the t···【Read More】

  Update: 2026-03-31Source: Haiou HealthViews: 134